

## CASE SERIES

# Sugammadex use in liver transplantation: a case series and literature review

Leyla Iyilikci<sup>1</sup>, Sule Ozbilgin<sup>2</sup>, Mert Akan<sup>3</sup>, Sevda Ozkardesler<sup>1</sup>, Leyla Seden Duru<sup>4</sup>

*Professor, <sup>2</sup>Consultant, <sup>3</sup>Assistant Professor*

*Dept of Anesthesiology and Reanimation, Faculty of Medicine, Dokuz Eylül University, İzmir, (Turkey)*

*<sup>4</sup>Consultant, Dept of Anesthesiology and Reanimation, Hospital of İzmir University, İzmir, (Turkey)*

**Correspondence:** Dr. Mert Akan, Department of Anesthesiology, Dokuz Eylül University, Faculty of Medicine, Balçova, 35340, İzmir, (Turkey): Tel: +90 (232) 4122954, Fax: +90 (232) 4122800; E-mail: [mertakan@hotmail.com](mailto:mertakan@hotmail.com)

## ABSTRACT

Postoperative residual neuromuscular blockade is associated with significant morbidity in liver transplantation. We report postoperative outcomes of sugammadex in a case series of 6 adult patients underwent liver transplantation at our institution in 2013. Sugammadex administration did not lead to any differences in the patients' heart rates, mean arterial pressures and electrocardiograms. In this case series, we observed that administration of rocuronium and sugammadex was effective and safe in liver transplant recipients. Postoperative residual neuromuscular blockade reversal with sugammadex may reduce the risk of pulmonary complications in liver transplant recipients.

**Key words:** Liver transplantation; Sugammadex; Neuromuscular blockade; Endotracheal extubation; Rocuronium; Neuromuscular Nondepolarizing Agents

**Citation:** Iyilikci L, Ozbilgin S, Akan M, Ozkardesler S, Duru LS. Sugammadex use in liver transplantation: a case series and literature review. *Anaesth Pain & Intensive Care* 2015;19(3):376-379

## INTRODUCTION

Due to developments in surgical techniques, expansion of indications for transplantation, better understanding of pathophysiology and perioperative care, today more and more liver transplants are performed in many centers.<sup>1,2</sup>

Liver transplantation necessitates anesthesia management that requires invasive hemodynamic monitoring, rapid and excessive transfusions, frequent and close follow-up of coagulation parameters with thromboelastography, values of blood gases and blood biochemistry.<sup>3</sup> Liver transplantation is a surgical procedure performed in high-risk patients, and the length of the surgery is usually not short and varies from one center to another. Therefore, if anesthesiologists plan to extubate the patient, they should consider postoperative residual curarization developing due to prolonged effects of muscle relaxant agents.

Residual curarization is still a common and an important problem in modern anesthesia, posing a serious threat to patient safety.<sup>4</sup> Therefore, it is

of more importance in liver transplant anesthesia in which the length of surgery is significantly longer. Nowadays, for traditional decurarization, cholinesterase inhibitors are widely used in combination with muscarinic antagonists. In recent years, use of sugammadex, a modified  $\gamma$ -cyclodextrin, in the steroidal neuromuscular agents has been a new alternative to traditional decurarization process performed with cholinesterase inhibitors.<sup>5-7</sup>

Sugammadex is used for the selective and rapid reversal of neuromuscular block. In several human and animal studies, it has been demonstrated that sugammadex can reverse rocuronium-induced deep neuromuscular blockade without leading to muscle weakness.<sup>8</sup> Therefore, in recent years, it has gained popularity in the practice of anesthesia. Since sugammadex provides quick and unproblematic recovery, now it is preferred by anesthesiologists more and used in anesthesia management more widely.

## CASE SERIES

Following the institutional Noninvasive Clinical

Research Ethics Committee approval, the data about 6 adult patients who were extubated in the operating room right after the liver transplantation procedure and received at least one dose of sugammadex during 2013 were analyzed. Prior to the procedure, vascular access was established in all cases, and electrocardiogram (ECG), arterial blood pressure, peripheral oxygen saturation (SpO<sub>2</sub>) and body temperature were monitored (Hewlett Packard, M1094B-Saronno, Italy). All the patients were given oxygen with a face mask at a rate of 4-6 L / min. To prevent aspiration, a H<sub>2</sub> receptor antagonist was administered intravenously 15-20 minutes before the process. All the patients underwent standard general anesthesia. Anesthesia was induced with inj. remifentanyl 0.1-0.2 µg/kg, thiopental sodium 3-5 mg/kg and rocuronium 1 mg/kg administered intravenously (IV). After orotracheal intubation, further monitoring of the patients was performed through invasive arterial catheterization and pulmonary artery catheterization. Anesthesia was maintained with desflurane (end-tidal 4-5%), inj. remifentanyl 0.05-0.2 µg/kg/min and inj. rocuronium 0.4 mg/kg/hr. While coagulation parameters were

monitored with thromboelastography, for the monitoring of ventilation parameters, arterial blood gases and EtCO<sub>2</sub> were used. During the surgery, neuromuscular monitoring (TOF Guard iNMT, Biomet International Odense, Denmark) was performed. Immediately after the operation, sugammadex 4 mg/kg IV was administered to hemodynamically and metabolically stable patients and these suitable patients were extubated without problem when the TOF ratio of 0.9 was reached in the operating room. All the patients were transferred to the intensive care unit.

Characteristics of the patients are shown in Table 1. Standard monitoring including neuromuscular monitoring (TOF) was applied to all patients. Only in two cases, TOF could not be used for neuromuscular monitoring due to some technical problem. In the patients who were not monitored with TOF, rocuronium infusion was discontinued 30 min before the operation ended. The patients were extubated without problem after sugammadex 4 mg/kg IV was administered. Sugammadex administration did not lead to any differences in

Table 1: Characteristics of the cases

Cases	Anthropo-metric Measurements	Donor type	Diagnosis	Anesth time (min)	Dose of roc. (mg)	Dose of sug. (mg)	Re-intubation	Transfusion (unit)
Case 1	Age: 48 Weight: 94 kg Height: 1,65 m BMI: 34,81 kg/m <sup>2</sup>	Cadaver	HBV-related liver cirrhosis	600	460	400	No	No RBC FFP 6
Case 2	Age: 40 Weight: 55 kg Height: 1,55 m BMI: 22,91 kg/m <sup>2</sup>	Cadaver	HBV- related liver cirrhosis	500	264	200	No	No RBC FFP 4
Case 3	Age: 60 Weight: 63 kg Height 1,55 m BMI: 26,25 kg/m <sup>2</sup>	Donor	Unknown cause	650	340	240	No	RBC 2 FFP 2 Thrombocyte 2
Case 4	Age: 48 Weight: 78 kg Height: 1,72 m BMI: 26,82 kg/m <sup>2</sup>	Donor	Cryptogenic liver cirrhosis	510	850	400	Yes	RBC 3 FFP 5 Thrombocyte 4
Case 5	Age: 54 Weight:65 kg Height: 1,63 m BMI: 24,52 kg/m <sup>2</sup>	Donor	HCV-HCC	640	340	260	No	RBC 4 FFP 5 Thrombocyte 1
Case 6	Age: 33 Weight: 80 kg Height: 1,90 m BMI: 22,22 kg/m <sup>2</sup>	Cadaver	Wilson cirrhosis	680		320	No	RBC 2 FFP 10 Thrombocyte 1

RBC = Red Blood Cell; FFP = Fresh Frozen Plasma; Roc. = Rocuronium; Sug. = sugammadex

the patients' heart rates, mean arterial pressures and electrocardiograms.

When the patients were transferred to the intensive care unit, they were conscious and cooperative, and breathing spontaneously with 4-6 L/min of oxygen support from a face mask. Adequate pain palliation could not be achieved in one of the patients because she could not use the patient-controlled analgesia (PCA) pump effectively in the intensive care unit and she was re-intubated due to severe agitation one hour after extubation.

In other patients, neither signs of residual curarization nor other side effects of sugammadex were observed.

## DISCUSSION

It takes longer to perform major surgery interventions such as liver transplantation, and in such operations, more neuromuscular blockers are required in order to achieve adequate muscle relaxation. Hence, in such operations there is a risk of residual curarization.<sup>6,9</sup> Among the well-known factors affecting postoperative residual block are type and dose of muscle relaxants used, administration of additional intraoperative doses, patient's clinical characteristics, and type and length of surgery.<sup>10</sup>

Prolongation of neuromuscular block and mechanical ventilation requirement resulting from the residual neuromuscular block during the postoperative period lead to increases in postoperative morbidity.<sup>4</sup> Atelectasis is a complication related with prolonged mechanical ventilation and it is associated with postoperative pulmonary complications such as pneumonia.<sup>11</sup> Therefore, in cases requiring muscle relaxation, continuous, objective neuromuscular monitoring should be performed and residual block should be avoided.

It is known that organ failure alone is a risk factor for residual block.<sup>11</sup> Thus, it is essential that respiratory and upper airway muscles of liver transplant patients should not be damaged, and that the patients should get rid of secretions by coughing. Residual block also destroys the respiratory response to hypoxia.<sup>12</sup> Therefore, recovery should be quickened by administering an agent for the reversal of neuromuscular blockade. Concomitant use of cholinesterase inhibitors and muscarinic antagonists is a safe and effective method to reverse residual block; however, their effects are limited in such cases as the complete reversal of deep

residual blockade and they lead to tachycardia, bradycardia, dry mouth, and emesis.<sup>5,13</sup> In liver transplant patients, these undesirable side effects might adversely affect their healing process during the postoperative period; thus, we administered sugammadex and also sugammadex is an ideal agent that can be used for the reversal of deep and shallow neuromuscular blockade.<sup>5,14</sup> Sugammadex is a modified gamma-cyclodextrin molecule introduced to the market recently. Sugammadex acts as a synthetic receptor by encapsulating steroidal neuromuscular blocking agents (NMBA) and promoting NMBA's disassociation from the nicotinic acetylcholine receptor.<sup>14-16</sup> No metabolites of sugammadex have been observed; it is excreted in the urine. For liver transplant patients, the absence of drug metabolites is important. Another important advantage of sugammadex is that it can reverse any level of a block. Sacan et al.<sup>17</sup> confirmed that sugammadex could rapidly reverse moderate rocuronium-induced neuromuscular blockade without any undesirable side effects. Most importantly, sugammadex promotes rapid and complete reversal and does not cause dry mouth which is common after surgeries in which cholinesterase inhibitors are used. Ledowski et al.<sup>18</sup> reported postoperative residual neuromuscular blockade reversal with sugammadex was associated with the lowest rate of postoperative nausea and vomiting and may reduce the risk of pulmonary complications in elderly ASA 3/4 patients.

After liver transplantation, early extubation can be safely achieved. For the successful extubation of a liver transplant patient, the patient should be comprehensively evaluated by an experienced anesthesiologist.<sup>19</sup> Skurzak et al.<sup>20</sup> performed early extubation in 594 liver transplant patients in the operating room based on a SORELTS scoring prepared by them and none of the patients were re-intubated in the first 48 hours post-operation. We decided to achieve extubation in patients who did not receive much blood or blood product transfusion, had stable hemodynamics/metabolic profile and developed no complications during the surgery. Sugammadex administration did not lead to any differences in the patients' heart rates, mean arterial pressures and electrocardiograms. Although the respiratory signs and arterial blood gases were normal, one patient was re-intubated in the intensive care unit because of severe agitation related with inadequate pain palliation.

In this case series, we observed that administration of rocuronium and sugammadex was quite effective

and safe in liver transplant recipients. Postoperative residual neuromuscular blockade reversal with sugammadex may reduce the risk of pulmonary complications in liver transplant recipients. But before suggesting its routine use in liver transplant patients, the results of large randomised

controlled trials should be awaited.

**Conflict of interest:** There is no potential conflict of interest or source of funding to declare.

**Author Contribution:** All the authors contributed in concept, manuscript preparation and review.

## REFERENCES

- Mehrabi A, Fonouni H, Müller SA, Schmidt J. Current concepts in transplant surgery: liver transplantation today. *Langenbecks Arch Surg* 2008;393:245–260. [PubMed] [Free full text]
- de Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ. Minimizing blood loss in liver transplantation: progress through research and evolution of techniques. *Dig Surg* 2005;22:265–75. [PubMed] [Free full text]
- Mandel MS, Tsou YM. The Development of Perioperative Practices for Liver Transplantation: Advances and Current Trends. *J Chin Med Assoc.* 2008 Sep;71(9):435-41. [PubMed] [Free full text] doi: 10.1016/S1726-4901(08)70145-X.
- Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of current management of neuromuscular block in the United States and Europe. *Anesth Analg.* 2010 Jul;111(1):110-9. [PubMed] [Free full text] doi: 10.1213/ANE.0b013e3181c07428.
- Kim KS, Lew SH, Cho HY, Cheong MA. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. *Anesth Analg.* 2002 Dec;95(6):1656-60. [PubMed] [Free full text]
- Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. *Br J Anaesth.* 2008 May;100(5):622-30. [PubMed] [Free full text] doi: 10.1093/bja/aen037.
- Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. *Eur J Anaesthesiol.* 2010 Oct;27(10):874-81. [PubMed] [Free full text] doi: 10.1097/EJA.0b013e32833d56b7.
- Bom A, Epemolu O, Hope F, Rutherford S, Thomson K. Selective relaxant binding agents for neuromuscular blockade. *Curr Opin Pharmacol* 2007;7:298-302. [PubMed] [Free full text]
- Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. *Anesth Analg.* 2008 Jul;107(1):130-7. [PubMed] [Free full text] doi: 10.1213/ane.0b013e31816d1268.
- McCaul C, Tobin E, Boylan JF, McShane AJ. Atracurium is associated with postoperative residual curarization. *Br J Anaesth* 2002;89:766-769. [PubMed] [Free full text]
- Kianfar AA, Ahmadi ZH, Mirhossein SM, Jamaati H, Kashani BS, Mohajerani SA, et al. Ultra fast-track extubation in heart transplant surgery patients. *Int J Crit Illn Inj Sci.* 2015 Apr-Jun;5(2):89-92. [PubMed] [Free full text] doi: 10.4103/2229-5151.158394.
- Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. *Anesthesiology* 1993;78:693-9. [PubMed] [Free full text]
- Caldwell JE. Reversal or residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. *Anesth Analg* 1995;80(6):1168–1174. [PubMed] [Free full text]
- Yang LP, Keam S J. Sugammadex: a review of its use in anaesthetic practice. *Drugs.* 2009;69(7):919-42. [PubMed] [Free full text] doi: 10.2165/00003495-200969070-00008.
- Adam JM, Bennet DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. *J Med Chem* 2002;45(9):1806-16. [PubMed]
- Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. *Anesthesiology.* 2003 Sep;99(3):632-7; discussion 6A. [PubMed] [Free full text]
- Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with Neostigmine-Glycopyrrolate and Edrophonium-Atropine. *Anesth Analg* 2007;104(3):569-74. [PubMed]
- Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. *Eur J Anaesthesiol.* 2014 Aug;31(8):423-9. [PubMed] [Free full text] doi: 10.1097/EJA.000000000000010.
- Wu J, Rastogi V, Zheng SS. Clinical practice of early extubation after liver transplantation. *Hepatobiliary Pancreat Dis Int* 2012;11(6):577-85. [PubMed] [Free full text]
- Skurzak S, Stratta C, Schellino MM, Fop F, Andruetto P, Gallo M, et al. Extubation score in the operating room after liver transplantation. *Acta Anaesthesiol Scand.* 2010 Sep;54(8):970-8. [PubMed] [Free full text] doi: 10.1111/j.1399-6576.2010.02274.x.

